Skip to content

Homepage

Author: NervGen Pharma Corp.

Posted Date:

May 26, 2026

NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study

NervGen Pharma Corp.

May 26, 2026
NervGen Announces Pricing of US$60.0 Million Public Offering of Securities

NervGen Pharma Corp.

May 23, 2026
NervGen Announces Proposed Public Offering of Securities

NervGen Pharma Corp.

May 23, 2026
NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates

NervGen Pharma Corp.

May 22, 2026
NervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer

NervGen Pharma Corp.

May 1, 2026
NervGen Pharma to Participate in the H.C. Wainwright “HCW@Home” Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference

NervGen Pharma Corp.

April 13, 2026
NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia

NervGen Pharma Corp.

April 7, 2026
NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates

NervGen Pharma Corp.

March 31, 2026
NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange

NervGen Pharma Corp.

March 13, 2026
NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs

NervGen Pharma Corp.

March 4, 2026

1 2